Clinical trial · Interventional
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
Evaluating the Implementation and Impact of Navigator-delivered ePRO Home Symptom Monitoring and Management
NCT04809740CI-TRIAL-00114971active not recruitingN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites and assess the impact of Home ePRO on clinical and utilization outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Navigator-delivered Home ePRO | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patient Group
- description
- Patients from UAB/MCI enrolled
- interventionNames
- Other: Navigator-delivered Home ePRO
Primary outcomes (1)
- measure
- Service Penetration
- timeFrame
- up to 3 months of starting a treatment for cancer
- description
- % of eligible patients enrolled
Secondary outcomes (9)
- measure
- Proportion of Alerts Closed Within 48 Hours
- timeFrame
- up to 48 hours
- description
- alerts are measured by abstracting alert data from the ePRO database
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patient Group: * Age ≥18 * Cancer patients at participating institution * Receipt of chemotherapy, targeted therapy, and immunotherapy at participating institution from 2019-2026. Exclusion Criteria: \- Second opinion only at participating institution.
References
Publications (2)
- DERIVEDRocque GB, Henderson NL, Dent DN, Padalkar TV, Hendrix E, Smith CS, Odom JN, Kaufmann T, Huang CS, McGowan C, Pierce JY, Basch EM, Smith JD, Stover AM. Barriers encountered and implementation strategies deployed to facilitate real-world remote symptom monitoring in patients receiving active cancer treatment. Front Health Serv. 2026 Aug 12;6:1875180. doi: 10.3389/frhs.2026.1875180. eCollection 2026. PMID 42656729
- DERIVEDRocque GB, Dionne-Odom JN, Stover AM, Daniel CL, Azuero A, Huang CS, Ingram SA, Franks JA, Caston NE, Dent AN, Basch EM, Jackson BE, Howell D, Weiner BJ, Pierce JY. Evaluating the implementation and impact of navigator-supported remote symptom monitoring and management: a protocol for a hybrid type 2 clinical trial. BMC Health Serv Res. 2022 Apr 22;22(1):538. doi: 10.1186/s12913-022-07914-6. PMID 35459238